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Telomere attrition unleashes genomic instability, promoting cancer development. Once estab-
lished, however, themalignant clone often re-establishes genomic stability through overexpression
of telomerase. In two papers, one in this issue ofCell and one in the subsequent issue, DePinho and
colleagues explore the consequences of telomerase re-expression and its validity as a therapeutic
target in mouse models of cancer.Telomere attrition induces a particularly
invidious form of genomic instability.
Once these protective caps have eroded,
the naked ends of the chromosomes
appear as double-stranded DNA (dsDNA)
breaks to cell, yet there is no correct DNA
repair solution other than restitution of an
intact telomere. In the absence of p53, the
cell attempts to repair this phantom
‘‘break,’’ or naked end of the chromo-
some. If this repair is performed in G2
phase of the cell cycle, after DNA replica-
tion, a common solution is to join the orig-
inal and the replicated chromosomes
together. This generates an end-to-end
chromosome fusion, the cytogenetic hall-
mark of telomere attrition (Gisselsson
et al., 2001; Maser et al., 2007; O’Hagan
et al., 2002). During mitosis, the two
centromeres are pulled to opposite
daughter cells, with the intervening
chromosomal material ultimately broken
during cytokinesis. This leads to two
daughter cells with genomic rearrange-
ments and a whole slew of authentic
dsDNA breaks. In the short term, this
genomic evolution can repeat in both
daughter cells with every cell cycle,
driving rapid genome evolution in expo-
nentially increasing numbers of com-
peting subclones (Bignell et al., 2007).
In the medium term, natural selection
weeds out the subclones with deleterious
rearrangements and fosters those with
enhanced malignant potential. In the
long term, however, unchecked genomic
instability resulting from telomere attri-
tion is disadvantageous: mice born with
depleted telomere reserves fail to thrive,exhibit organ atrophy, and display poor
proliferative response among epithelial
and hematological lineages (Lee et al.,
1998).
Surprisingly, though, many cancers re-
express telomerase in advanced stages
of malignancy (Gisselsson et al., 2001;
Hashimoto et al., 2008), and this reacti-
vation may reduce the devastation
wreaked by end-to-end chromosome
fusions (Campbell et al., 2010). Having
painstakingly dissected the multitudinous
effects of telomere erosion in mouse
models of cancer and aging over the
last 10–15 years, DePinho’s laboratory
now presents two studies on the flip
side, that of telomerase (mTert) re-
expression (Ding et al., 2012; Hu et al.,
2012).
In the first study, Ding et al. start with
a mouse model prone to prostate cancer
through targeted ablation of p53, Pten,
and mTert (telomerase reverse transcrip-
tase). They then engineer an inducible
version of the mTert gene to allow reacti-
vation of telomerase. Control mice, which
are missing p53 and Pten but maintain
telomere function, universally develop
invasive adenocarcinoma of the prostate
by 24 weeks of age. In contrast, the
prostate tumors that developed in p53/
Pten-deficient mice are smaller, less
aggressive, and less invasive when telo-
merase is lost and telomere erosion is
established. Thus, deletion of these two
key tumor suppressor genes pushes cells
a long way toward prostate cancer, and
the disadvantages of ongoing genomic
instability mediated by irreparably shortCell 148,telomeres outweigh any potential gains
from further genomic evolution. When
Ding et al. re-express telomerase in the
prostates of mice with depleted telo-
meres, however, an especially virulent
cancer develops, which is bulky, aggres-
sive, invasive, and capable of metastasis
to the lumbar spine. Genome profiling of
these super-aggressive tumors reveals
many copy number aberrations, overlap-
ping with those seen in human prostate
cancers (Beroukhim et al., 2010). Among
these aberrations, loss of Smad4 is
particularly prevalent, and mice with loss
of p53, Pten, and Smad4 in the prostate
recapitulate the more aggressive pheno-
type seen with telomerase re-expression,
including the propensity to bone metas-
tasis (Figure 1).
The model of telomere erosion that
emerges from these findings is rather
intriguing, not unlike trying to climb up
a downward escalator. Presumably,
Smad4 deletion and other advantageous
lesions were indeed developing in iso-
lated p53/Pten-deficient prostate cells
with depleted telomeres, but the relent-
less downward effects of unfettered
genome instability prevented these
clones from ever reaching the summit of
invasive and metastatic malignancy.
When this downward pressure was
switched off through re-expression of
telomerase, however, the clones could
escalate their malignant potential to new
levels.
These findings raise the important
question of whether reactivation of telo-
merase is a valid therapeutic target, andFebruary 17, 2012 ª2012 Elsevier Inc. 633
634 Cell 148, February 17, 2012 ª2012 Elsevit is this hypothesis that is addressed in
the second of the papers reported here.
Hu et al. introduce a tamoxifen-inducible
mTert allele into Atm-deficient mice that
is susceptible to T cell lymphoma. They
uncover patterns of malignancy akin to
those described above for prostate
cancer: lymphomas in mice with telomere
erosion plus Atm deficiency are slower to
evolve than tumors with only Atm defi-
ciency. However, as Ding et al. found,
re-expression of telomerase increases
malignant potential, spread of the tumor,
and the frequency of clonal copy number
alterations.
To model what potential benefits might
arise from inhibiting telomerase reactiva-
tion in human tumors, Hu et al. then seri-
ally xenograft 11 tumor lines from this
mouse model into donor mice with or
without concomitant tamoxifen. It took
three generations of xenografts for the
re-established telomeres to erode again
in mice with no tamoxifen, but once they
did, six lines completely fail to develop
tumors in recipients, and 3 lines exhibit
much slower engraftment than when
tamoxifen (and therefore telomerase) is
maintained throughout. Strikingly, these
three lines re-attain full malignant poten-
tial upon a fourth serial transplant, even
in the absence of tamoxifen. The implica-
tion is that tumors that are dependent
on telomerase reactivation are indeed
sensitive to loss of telomerase and telo-
mere attrition, but this may be bypassed
by other pathways. In particular, Hu and
colleagues proceed to show that the
lines escaping from the crisis induced
by withdrawal of tamoxifen activate
a pathway known as alternative length-Figure 1. The Telomere Crisis Model of
Cancer Evolution
Cancers initially evolve slowly, gradually acquiring
spontaneous mutations (yellow dots). With
increasing numbers of cell divisions, however,
telomeres erode, and this induces a rapid increase
in both the number of mutations (red dots) and the
subclonal heterogeneity in the organ. Out of these
competing subclones, one emerges with more
malignant potential. As Ding et al. (2012) show, it is
to this clone’s selective advantage to re-establish
genomic stability through re-expression of telo-
merase. A period of relative genomic stability may
follow, but this equilibrium can be disrupted by
inhibition of telomerase. Hu et al. (2012) find that,
after initial therapeutic benefit, such inhibition
induces a second telomere crisis, again with rapid
acquisition of new mutations (green dots) and
subclonal heterogeneity.
ier Inc.ening of telomeres. This activation is
associated with enhanced signaling
through networks involving mitochondrial
function and reactive oxygen species,
centered on genomic amplification and
overexpression of the PGC-1b gene.
Inhibition of this gene by small hairpin
RNA causes significant reduction of
tumor potency in those lymphomas
with activated pathways for alternative
lengthening of telomeres but causes
minimal effect on lymphomas, which
had steady telomerase levels throughout
xenografting.
These elegant studies illustrate the
perfidy of cancer in the face of well-inten-
tioned therapeutic strategies. Clones that
re-express telomerase can overcome
the genomic crisis induced by telomere
erosion; inhibition of this very telomerase
is then bypassed in the cancer through
alternative pathways of telomere main-
tenance. Telomerase inhibitors have
entered phase I/II clinical trials in several
malignancies. The data presented here
show that there may well be considerable
therapeutic benefit from such agents, but
they may ultimately induce the very insta-
bility that evolves the cancer genome to
a drug-resistant state. Yet, as Hu et al.
show, with every therapeutic bypass,
the clone makes sacrifices, and these
become themselves rational therapeutic
targets. And so, like an ever more sophis-
ticated arms race, the battle between
cancer and clinician escalates.REFERENCES
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Using a fluorescence method called colocalization single-molecule spectroscopy (CoSMoS),
Friedman and Gelles dissect the kinetics of transcription initiation at a bacterial promoter. Ulti-
mately, CoSMoS could greatly aid the study of the effects of DNA sequence and transcription
factors on both prokaryotic and eukaryotic promoters.The first step in gene expression is the
recognition of promoter DNA by the basal
transcription machinery, that is, RNA
polymerase (RNAP) and a s factor in
bacteria or the basal transcription factors
in eukaryotes. The initiation machinery
then unwinds the DNA in the region
of the transcription start site to form
an open complex, and RNA synthesis
commences. It has long been recognized
that the initiation complex passes through
multiple intermediates on the path to
formation of an open complex, with the
efficiency of each step traceable in prin-
ciple to the promoter DNA sequence
(Record et al., 1996). Remarkable diver-
sity exists in the efficiency with which
different promoters produce RNA. Esti-
mates of this diversity range over several
orders of magnitude.
Predicting transcription output from
promoter sequence is an important goal
of genome-scale biology, but making
accurate predictions from sequence
alone has been difficult. Multiple factors
have contributed to the prediction pro-blem, including the extraordinary difficulty
of identifying the intermediates in the
transcription initiation mechanism, the
challenge of measuring the forward and
reverse rates associated with their forma-
tion and decay, and the need to assign the
promoter sequences responsible for each
transition. Elucidating even a subset of
these intermediates and rates for a few
model bacterial promoters has occupied
transcription researchers for decades.
CoSMoS, as described in this issue of
Cell (Friedman and Gelles, 2012), has the
potential to greatly facilitate the kinetic
analysis of transcription initiation.
Classic experiments by McClure and
coworkers in the late 1970s and early
1980s (for instance, McClure, 1980) led
to a paradigm for the mechanism of tran-
scription initiation in which the formation
of open complexes could be described
as the product of two parameters, an
RNAP concentration-dependent equilib-
rium constant for promoter DNA binding
(sometimes referred to as KB) and a
composite second-order rate constantfor the DNA unwinding steps (sometimes
called kf). However, as our understanding
of the initiation reaction has grown to
include multiple steps (Saecker et al.,
2011), actually determining the rates of
formation and decay of the individual
intermediates has required considerable
ingenuity, including the use of changes in
temperature, a range of different solutes
and perturbants, and rapid timescale
chemical probing of DNA conformation.
The introduction of transcription factors
into the equation adds further challenges
for analysis. The identities of the transcrip-
tion factors sometimes are known but
sometimes are not. Even when the identi-
ties of the factors are known, it has not
always been possible to purify them to
homogeneity without loss of activity.
Although the promoter targets of these
factors are usually determined by DNA-
binding sites near the specific promoter
(Browning and Busby, 2004), sometimes
transcription factors act simply by binding
to the RNAP itself without binding to
DNA. In this case, their specificities areFebruary 17, 2012 ª2012 Elsevier Inc. 635
